$Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial$

Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial

Bibliographic Details
Main Authors:	Francine Foss, Steven Horwitz, Barbara Pro, H. Miles Prince, Lubomir Sokol, Barbara Balser, Julie Wolfson, Bertrand Coiffier
Format:	Article
Language:	English
Published:	BMC 2017-09-01
Series:	Journal of Hematology & Oncology
Online Access:	http://link.springer.com/article/10.1186/s13045-017-0518-8

Similar Items

Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
by: Francine Foss, et al.
Published: (2016-03-01)

A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients
by: Cinzia Pellegrini, et al.
Published: (2016-04-01)

Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T‐cell lymphoma
by: Cesar Gentille, et al.
Published: (2022-07-01)

Novel Therapies and Approaches to Relapsed/Refractory HL Beyond Chemotherapy
by: Alain Antoine Mina, et al.
Published: (2019-03-01)

Romidepsin in the treatment of cutaneous T-cell lymphoma
by: Jain S, et al.
Published: (2011-04-01)

Pharmacokinetics and Immunological Effects of Romidepsin in Rhesus Macaques
by: Adam J. Kleinman, et al.
Published: (2020-12-01)

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo.
by: Ole S Søgaard, et al.
Published: (2015-09-01)

Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin
by: Nasreddine El Omari, et al.
Published: (2023-08-01)

Synergistic Effect Of Simvastatin And Romidepsin On Gamma-Globin Gene Induction
by: Hussain Habibi, et al.
Published: (2018-08-01)

Simvastatin-romidepsin combination kills bladder cancer cells synergistically
by: Kazuki Okubo, et al.
Published: (2021-09-01)

Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma
by: Roch Houot, et al.
Published: (2022-02-01)

Romidepsin controls chronic lymphocytic leukemia in a patient with mycosis fungoides
by: David M. Lemchak, et al.
Published: (2016-11-01)

P1115: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2
by: Jan Walewski, et al.
Published: (2023-08-01)

Romidepsin Induces G2/M Phase Arrest and Apoptosis in Cholangiocarcinoma Cells
by: Pihong Li MD, et al.
Published: (2020-10-01)

P1124: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL EXPANSION PHASE: OUTCOMES BY BASELINE HISTOLOGY
by: Neha Mehta-Shah, et al.
Published: (2023-08-01)

Immunotoxin – a new treatment option in patients with relapsed and refractory Hodgkin lymphoma
by: Novakovic Barbara Jezersek
Published: (2015-12-01)

Single romidepsin infusions do not increase HIV expression in persons on ART (A5315)
by: D. McMahon, et al.
Published: (2017-12-01)

Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201)
by: Yuqin Song, et al.
Published: (2022-07-01)

The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
by: Jeremy A. Meier, et al.
Published: (2022-02-01)

Prolonged refractory dysphagia in polymyositis
by: Thomas Mathew, et al.
Published: (2015-01-01)

Multi-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque Controllers.
by: Benjamin B Policicchio, et al.
Published: (2016-09-01)

Relapsed/Refractory Hodgkin Lymphoma
by: Semira Sheikh, et al.
Published: (2018-06-01)

Radiopharmaceuticals for Relapsed or Refractory Leukemias
by: Charles A. Kunos, et al.
Published: (2019-02-01)

Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial
by: Robert J. Kreitman, et al.
Published: (2021-02-01)

Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma
by: Hujun Li, et al.
Published: (2022-10-01)

Refractory Temporomandibular Joint Dislocation – Reduction Using the Wrist Pivot Method
by: Vincent W.M. Lum, et al.
Published: (2017-10-01)

The Role of Rituximab in Lymphomas
by: Bertrand Coiffier
Published: (2002-01-01)

Deoxyspergualin in relapsing and refractory Wegener's granulomatosis.
by: Flossmann, O, et al.
Published: (2009)

Blinatumomab in Relapsed/Refractory Burkitt Lymphoma
by: Jeanne Bohler, et al.
Published: (2022-12-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Carfilzomib for relapsed and refractory multiple myeloma
by: Groen K, et al.
Published: (2019-04-01)

Selinexor in relapsed/refractory multiple myeloma
by: Joshua Richter, et al.
Published: (2020-06-01)

Refractory relapsing polychondritis: challenges and solutions
by: Kemta Lekpa F, et al.
Published: (2018-01-01)

The histone deacetylase inhibitor romidepsin spares normal tissues while acting as an effective radiosensitiser in bladder tumours in vivo
by: Paillas, S, et al.
Published: (2020)

P1195: A REAL WORLD EXPERIENCE OF COMBINED TREATMENT WITH ROMIDEPSIN AND AZACITIDINE IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA.
by: M. Kalac, et al.
Published: (2022-06-01)

Efficacy and Treatment-Related Adverse Events of Romidepsin in PTCL Clinical Studies: A Systematic Review and Meta-Analysis
by: Jun Du, et al.
Published: (2021-11-01)

Different regimens of romidepsin administration for reversion of SIV latency in a rhesus macaque model of complete virus control
by: A. Kleinman, et al.
Published: (2019-07-01)

S191: PIVOTAL PHASE 2 MONUMENTAL-1 RESULTS OF TALQUETAMAB (TAL), A GPRC5DXCD3 BISPECIFIC ANTIBODY (BSAB), FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
by: Cyrille Touzeau, et al.
Published: (2023-08-01)